GRIN2B Foundation is pleased to announce $21,600 in new research funding to promote scientific understanding of the rare genetic condition known as GRIN2B-Related Neurodevelopmental Disorder. Combined with our grant funding from February, this brings our 2026 award total to $118,780.

Our most recent award is to Chad R. Camp, MPH, PhD, a postdoctoral fellow at the University of Colorado Anschutz Medical Campus in Dr. Tim Benke’s lab, for his project entitled:

GluN2B-CaMKII Interaction in Human GRIN2B Variants of Intellectual Disability and Autism

His research focuses on a part of the GRIN2B protein called the C-terminal tail:  a region where roughly one-third of disease-associated GRIN2B variants occur, yet one that current testing methods often fail to evaluate, leaving many variants labeled “inconclusive.” Rather than relying on traditional electrical-current testing, Dr. Camp will examine whether these variants disrupt the receptor’s ability to bind with key proteins essential for learning, memory, and healthy brain connections. This work aims to give more GRIN2B families clear answers about their child’s specific variant, while opening new doors for future diagnostics and treatments.

This research project was submitted to our 2025 Request for Proposals (RFP).

Thank you to everyone who continues to donate, fundraise, and champion our mission. Your generosity is what makes grants like this one possible, and we’re so grateful for your continued support.

 As a reminder, September is our Bee Active for GRIN2B fundraiser, and we’re already 91% of the way to our $65,000 goal! Please consider donating today to help us close the gap. Your support allows us to keep awarding high-impact research grants like this one, bringing us closer to real treatments for GRIN2B families every single day.

DONATE TODAY TO CONTINUE SUPPORTING RESEARCH

Read about our three previously announced 2026 grants here.